Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.01.
(d)On July31, 2017, Tyme Technologies, Inc. (the “Company”), in accordance with the authority granted by the Company’s board of directors, listed its shares of common stock (the “Common Stock”), which were previously quoted on the OTCQB® Venture Market (“OTC”) under the ticker symbol “TYMI,” on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “TYME.” In connection with such action, the listing and trading of the Common Stock on OTC ceased at market close on July28, 2017, and trading of the Common Stock commenced on Nasdaq upon the opening of business on July31, 2017.
A copy of the press release issued by the Company announcing the transfer to Nasdaq is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 3.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit is filed with this report:
|
Exhibit No. |
Description |
| 99.1 | Press release issued by the Company on July27, 2017. |
TYME TECHNOLOGIES, INC. ExhibitEX-99.1 2 d435902dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tyme Announces Uplisting to NASDAQ Capital Market Under New Symbol “TYME” on July 31,…To view the full exhibit click here
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
